Novartis Ag

Ciba-geigy Corporation

Novartis Finance Corporation

Novartis Corporation

Novatis Ag

Hans-Georg Capraro

Guido Bold

Giorgio Caravatti

Marc Lang

Alexander Fassler

Jorg Frei

Satish Chandra Khanna

Jaroslav Stanek

Pascal Furet

Shripad S Bhagwat

Peter Traxler

Janis Karlis Lazdins

Paul William Manley

Carlos Garcia-Echeverria

Patricia Imbach

Andrea Vaupel

Peter Schneider

Frédéric Stauffer

Alexander F&auml;ssler

Heinz Steiner

Andreas Floersheimer

Peter Van Hoogevest

Jürg Zimmermann

Erfinders J Stanek

Wolfgang Karl-Diether Brill

J&uuml;rg Zimmermann

The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. 

Bicyclic amides as kinase inhibitors

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases

The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.

4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives

The invention relates to new 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof-alone or in combination with one or more other pharmaceutically active compounds-for the treatment of a disease, especially a proliferative disease, such as a tumour disease, a method for the treatment of such diseases in mammals, especially in humans, and the use of such a compound-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of a pharmaceutical composition (medicament) for the treatment especially of a proliferative disease, such as a tumour.

4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives

The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumor.

7H-pyrrolo[2,3-d]pyrimidine derivatives

The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour 

2-Amino-6-anilino-purine derivatives of the formula 1 in which the symbols are as defined in claim 1 are described. These compounds inhibit p34/cyclin Bkinase and can be used for treatment of hyperproliferative diseases, for example tumour diseases.

Purine derivatives and processes for their preparation

2-amino-6-anilino-purines and their use as medicaments

Anilinopeptide derivatives

There are described compounds of formula I*,

Antivirally active heterocyclic azahexane derivatives

The invention relates to compounds of formula (I):

Azahexane derivatives as substrate isosters of retroviral asparate proteases

There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl,

Combinations of HIV protease inhibitors with reverse transcriptase

Antiretroviral compounds (which are effective, for example, against HIV) of the formula I ##STR1## in which R.sub.1 is an acyl radical lower-alkoxy-lower-alkanoyl whose lower alkoxy radical is unsubstituted or is substituted by halogen, phenyl, lower alkoxy or a heterocyclic radical selected from piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolidinyl, thiazolyl, indolyl or 4H-1-benzopyranyl which is unsubstituted or substituted by oxo, hydroxyl, amino, lower alkyl, lower-alkoxycarbonyl and/or phenyl-lower-alkoxycarbonyl; lower alkanoyl which is unsubstituted or is substituted by one of the said unsubstituted or substituted heterocyclic radicals; arylcarbonyl or heterocyclylcarbonyl which are substituted by heterocyclyl or heterocyclyl-lower-alkyl; phenyl-lower-alkanoyl which is substituted by hydroxyl and lower alkyl; or arylsulfonyl;

Antiviral ethers of aspartate protease substrate isosteres

The invention relates to a novel process for the preparation of compounds of formula I ##STR1## wherein R.sub.1 is hydrogen or a suitable amino-protecting group,

Growing community of inventors

Rheinfelden, Switzerland

Hans-Georg Capraro